BibTex RIS Kaynak Göster

Metabolik sendromlu hastalarda nonalkolik yağlı karaciğer hastalığı ve hs-CRP arasındaki ilişki

Yıl 2010, Cilt: 32 Sayı: 1, 26 - 33, 11.03.2010

Elvan Amasyalı Fatih Kılıçlı , Ramazan Say Bülent Uygungelen Fettah Acıbucu

Öz

Özet

Amaç. Metabolik sendrom hastalarında gittikçe önem kazanan non-alkolik yağlı karaciğer hastalığının sıklığını ve hs-CRP ile arasındaki ilişkiyi araştırmaktır. Yöntem. Çalışmaya 26’sı erkek ve 34’ü kadın toplam 60 metabolik sendrom olgusu ile 21’i erkek ve 21’i kadın toplam 42 sağlıklı birey alındı. Bulgular. Metabolik sendromlu olgularımızda %78,3 oranında karaciğer yağlanmasının olduğu; hs-CRP değerlerinin bu hastalarda anlamlı derecede yüksek olduğu, bu artışın yağlanmanın derecesi ile doğru orantılı olduğu görüldü. Sonuç. hs-CRP artışı metabolik sendromlu hastalarda hepatosteatoza gidişi göstermektedir.

Anahtar sözcükler: Metabolik sendrom, karaciğer yağlanması, hs-CRP

 

Abstract

Aim. Our aim was to investigate the relationship between hs-CRP and non-alcoholic fatty liver disease with metabolic syndrome patients; that gradually gained importance. Methods. The study included 60 metabolic syndrome patients (26 males, 34 females) and 42 healthy individuals (21 male, 21 female). Results. As a result we found that the frequency of hepatosteatosis in our metabolic syndrome patients was found as 78.3%, hs-CRP levels were significantly elevated in these patients and this elevation showed a positive correlation with the grade of hepatosteatosis. Conclusion. Elevated hs-CRP shows progression to hepatosteatosis in patients with metabolic syndrome

Keywords: Metabolic syndrome, hepatosteatosis, hs-CRP

 

Anahtar Kelimeler

-

Kaynakça

  • Satman İ, Kocabay G. Diabet ve Karaciğer Yağlanması. Türkiye Klinikleri Tıp Bilimleri Dergisi 2006; 26: 1-12.
  • Oğuz A. Metabolik Sendrom. Özata M, Yönem A. (editörler): Endokrinoloji Metabolizma ve Diabet. 1. baskı. İstanbul Medical Yayıncılık; 2006: 550-63.
  • González AS, Guerrero DB, Soto MB, Díaz SP, Martinez-Olmos M, Vidal O. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. Eur J Clin Nutr 2006; 60: 802-9.
  • Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-7.
  • Şentürk O. Non alkolik yağlı karaciğer hastalığı (NAYKH). Folia 2004; 4 :12-20.
  • Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
  • Longo R, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, Crocè LS, Grigolato P. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 1995; 5: 281-5.
  • Reaven G. Role of İnsulin resistance in human disease. Diabetes 1988; 37: 1595-607
  • Acartürk G, Karaca E, Yüksel Ş, Çölbat M, Uslan İ, Karaman Ö, Paşalı Kilit T. Obezlerde Metabolik sendromun Dünya Sağlık Örgütü Erişkin Tedavi Paneli-III Kriterlerine Göre Karşılaştırılması. MN Dahili Tıp Bilimleri 2007; 2: 107-11.
  • Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
  • Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-8.
  • Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC, Hofman A, Witteman JC. Associations of C-reactive protein with measures of obesity, insulin resistance and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999; 19: 1986-91.
  • Pannacciulli N, Cantatore FP, Minenna A, Bellacicco M, Giorgino R, De Pergola G. C- reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int J Obes Relat Metab Disord 2001; 25: 1416-20.
  • Marques-Vidal P, Mazoyer E, Bongard V, Gourdy P, Ruidavets JB, Drouet L, Ferrières J. Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 2002; 25: 1371-7.
  • Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 2003; 168: 351-8.
  • Altınova A, Törüner F, Arslan E. Metabolik Sendromu Olan Tip 2 Diabetes Mellituslu Hastalarda Artmış Serum Duyarlı C-Reaktif Protein Düzeyleri. Endokrinolojide Yönelişler 2007; 6: 22-5.
  • Lee WY, Park JS, Noh SY, Rhee EJ, Sung KC, Kim BS, Kang JH, Kim SW, Lee MH, Park JR. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int J Cardiol 2004; 97: 101-6.
  • Laaksonen DE, Niskanen L, Nyyssönen K, Punnonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004; 47: 1403-10.
  • Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005; 54: 3252-7.
  • Nakanishi N, Shiraishi T, Wada M. C-reactive protein concentration is more strongly related to metabolic syndrome in women than in men: the Minoh Study. Circ J 2005; 69: 386-91.
  • Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14.719 initially healthy American women. Circulation 2003; 107: 391-7.
  • Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic Fatty Liver, Steatohepatitis and the Metabolic Syndrome. Hepatology 2003; 37: 917-23.
  • Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
  • Hui JM, Farrell GC. Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them. J Gastroenterol Hepatol 2003; 18: 1115-7.
  • Akbar DH, Kawther AH. Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we don’t know. Med Sci Monit 2006; 12: 23-6.
  • Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007; 22: 293-303.
  • Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005; 172: 899-905.
  • Bogdanova K, Poczatkova H, Uherkova L, Riegrova D, Rypka M, Feher J, Marchesini G, Vesely J. Non-alcoholic fatty liver disease (NAFLD)-a novel common aspect of the metabolic syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006; 150: 101-4.

Metabolik sendromlu hastalarda nonalkolik yağlı karaciğer hastalığı ve hs-CRP arasındaki ilişki

Yıl 2010, Cilt: 32 Sayı: 1, 26 - 33, 11.03.2010

Elvan Amasyalı Fatih Kılıçlı , Ramazan Say Bülent Uygungelen Fettah Acıbucu

Öz

Amaç. Metabolik sendrom hastalarında gittikçe önem kazanan non-alkolik yağlı karaciğer hastalığının sıklığını ve hs-CRP ile arasındaki ilişkiyi araştırmaktır. Yöntem. Çalışmaya 26’sı erkek ve 34’ü kadın toplam 60 metabolik sendrom olgusu ile 21’i erkek ve 21’i kadın toplam 42 sağlıklı birey alındı. Bulgular. Metabolik sendromlu olgularımızda %78,3 oranında karaciğer yağlanmasının olduğu; hs-CRP değerlerinin bu hastalarda anlamlı derecede yüksek olduğu, bu artışın yağlanmanın derecesi ile doğru orantılı olduğu görüldü. Sonuç. hs-CRP artışı metabolik sendromlu hastalarda hepatosteatoza gidişi göstermektedir

Anahtar Kelimeler

Metabolik sendrom karaciğer yağlanması hs-CRP

Kaynakça

  • Satman İ, Kocabay G. Diabet ve Karaciğer Yağlanması. Türkiye Klinikleri Tıp Bilimleri Dergisi 2006; 26: 1-12.
  • Oğuz A. Metabolik Sendrom. Özata M, Yönem A. (editörler): Endokrinoloji Metabolizma ve Diabet. 1. baskı. İstanbul Medical Yayıncılık; 2006: 550-63.
  • González AS, Guerrero DB, Soto MB, Díaz SP, Martinez-Olmos M, Vidal O. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. Eur J Clin Nutr 2006; 60: 802-9.
  • Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-7.
  • Şentürk O. Non alkolik yağlı karaciğer hastalığı (NAYKH). Folia 2004; 4 :12-20.
  • Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
  • Longo R, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, Crocè LS, Grigolato P. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 1995; 5: 281-5.
  • Reaven G. Role of İnsulin resistance in human disease. Diabetes 1988; 37: 1595-607
  • Acartürk G, Karaca E, Yüksel Ş, Çölbat M, Uslan İ, Karaman Ö, Paşalı Kilit T. Obezlerde Metabolik sendromun Dünya Sağlık Örgütü Erişkin Tedavi Paneli-III Kriterlerine Göre Karşılaştırılması. MN Dahili Tıp Bilimleri 2007; 2: 107-11.
  • Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
  • Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-8.
  • Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC, Hofman A, Witteman JC. Associations of C-reactive protein with measures of obesity, insulin resistance and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999; 19: 1986-91.
  • Pannacciulli N, Cantatore FP, Minenna A, Bellacicco M, Giorgino R, De Pergola G. C- reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int J Obes Relat Metab Disord 2001; 25: 1416-20.
  • Marques-Vidal P, Mazoyer E, Bongard V, Gourdy P, Ruidavets JB, Drouet L, Ferrières J. Prevalence of insulin resistance syndrome in southwestern France and its relationship with inflammatory and hemostatic markers. Diabetes Care 2002; 25: 1371-7.
  • Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 2003; 168: 351-8.
  • Altınova A, Törüner F, Arslan E. Metabolik Sendromu Olan Tip 2 Diabetes Mellituslu Hastalarda Artmış Serum Duyarlı C-Reaktif Protein Düzeyleri. Endokrinolojide Yönelişler 2007; 6: 22-5.
  • Lee WY, Park JS, Noh SY, Rhee EJ, Sung KC, Kim BS, Kang JH, Kim SW, Lee MH, Park JR. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int J Cardiol 2004; 97: 101-6.
  • Laaksonen DE, Niskanen L, Nyyssönen K, Punnonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004; 47: 1403-10.
  • Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005; 54: 3252-7.
  • Nakanishi N, Shiraishi T, Wada M. C-reactive protein concentration is more strongly related to metabolic syndrome in women than in men: the Minoh Study. Circ J 2005; 69: 386-91.
  • Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14.719 initially healthy American women. Circulation 2003; 107: 391-7.
  • Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic Fatty Liver, Steatohepatitis and the Metabolic Syndrome. Hepatology 2003; 37: 917-23.
  • Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
  • Hui JM, Farrell GC. Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them. J Gastroenterol Hepatol 2003; 18: 1115-7.
  • Akbar DH, Kawther AH. Non-alcoholic fatty liver disease and metabolic syndrome: what we know and what we don’t know. Med Sci Monit 2006; 12: 23-6.
  • Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007; 22: 293-303.
  • Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005; 172: 899-905.
  • Bogdanova K, Poczatkova H, Uherkova L, Riegrova D, Rypka M, Feher J, Marchesini G, Vesely J. Non-alcoholic fatty liver disease (NAFLD)-a novel common aspect of the metabolic syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006; 150: 101-4.
Toplam 28 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Bölüm Dahili Tıp Bilimleri Araştırma Yazıları
Yazarlar

Elvan Amasyalı

Fatih Kılıçlı

Ramazan Say

Bülent Uygungelen

Fettah Acıbucu

Yayımlanma Tarihi 11 Mart 2010
Yayımlandığı Sayı Yıl 2010Cilt: 32 Sayı: 1

Kaynak Göster

AMA Amasyalı E, Kılıçlı F, Say R, Uygungelen B, Acıbucu F. Metabolik sendromlu hastalarda nonalkolik yağlı karaciğer hastalığı ve hs-CRP arasındaki ilişki. CMJ. Mart 2010;32(1):26-33.